Literature DB >> 25359367

Bispecific antibodies rise again.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25359367     DOI： 10.1038/nrd4478

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  50 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

2.  Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.

Authors:  Boning Liu; Huaizu Guo; Jin Xu; Ting Qin; Qingcheng Guo; Nana Gu; Dapeng Zhang; Weizhu Qian; Jianxin Dai; Sheng Hou; Hao Wang; Yajun Guo
Journal:  MAbs       Date:  2017-12-20       Impact factor: 5.857

Review 3.  mRNA: A Novel Avenue to Antibody Therapy?

Authors:  Thomas Schlake; Moritz Thran; Katja Fiedler; Regina Heidenreich; Benjamin Petsch; Mariola Fotin-Mleczek
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

4.  Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Authors:  Christiane R Stadler; Hayat Bähr-Mahmud; Leyla Celik; Bernhard Hebich; Alexandra S Roth; René P Roth; Katalin Karikó; Özlem Türeci; Ugur Sahin
Journal:  Nat Med       Date:  2017-06-12       Impact factor: 53.440

5.  Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.

Authors:  Binyam Bezabeh; Ryan Fleming; Christine Fazenbaker; Haihong Zhong; Karen Coffman; Xiang-Qing Yu; Ching Ching Leow; Nerea Gibson; Susan Wilson; C Kendall Stover; Herren Wu; Changshou Gao; Nazzareno Dimasi
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

Review 6.  Programming Cell-Cell Interactions through Non-genetic Membrane Engineering.

Authors:  Clifford M Csizmar; Jacob R Petersburg; Carston R Wagner
Journal:  Cell Chem Biol       Date:  2018-06-14       Impact factor: 8.116

7.  A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets.

Authors:  John J Rhoden; Gregory L Dyas; Victor J Wroblewski
Journal:  J Biol Chem       Date:  2016-03-28       Impact factor: 5.157

8.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

Review 9.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

10.  p95HER2-T cell bispecific antibody for breast cancer treatment.

Authors:  Irene Rius Ruiz; Rocio Vicario; Beatriz Morancho; Cristina Bernadó Morales; Enrique J Arenas; Sylvia Herter; Anne Freimoser-Grundschober; Jitka Somandin; Johannes Sam; Oliver Ast; Águeda Martinez Barriocanal; Antonio Luque; Marta Escorihuela; Ismael Varela; Isabel Cuartas; Paolo Nuciforo; Roberta Fasani; Vicente Peg; Isabel Rubio; Javier Cortés; Violeta Serra; Santiago Escriva-de-Romani; Jeff Sperinde; Ahmed Chenna; Weidong Huang; John Winslow; Joan Albanell; Joan Seoane; Maurizio Scaltriti; Jose Baselga; Josep Tabernero; Pablo Umana; Marina Bacac; Cristina Saura; Christian Klein; Joaquín Arribas
Journal:  Sci Transl Med       Date:  2018-10-03       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.